Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection by Schüpbach, Jörg et al.
RESEARCH ARTICLE Open Access
Diagnostic performance of line-immunoassay
based algorithms for incident HIV-1 infection
Jörg Schüpbach1*, Leslie R Bisset1, Martin D Gebhardt2, Stephan Regenass3, Philippe Bürgisser4, Meri Gorgievski5,
Thomas Klimkait6, Corinne Andreutti7, Gladys Martinetti8, Christoph Niederhauser9, Sabine Yerly10, Stefan Pfister11,
Detlev Schultze12, Marcel Brandenberger13, Franziska Schöni-Affolter14, Alexandra U Scherrer15 and
Huldrych F Günthard15, for Swiss HIV Cohort Study
Abstract
Background: Serologic testing algorithms for recent HIV seroconversion (STARHS) provide important information
for HIV surveillance. We have previously demonstrated that a patient’s antibody reaction pattern in a confirmatory
line immunoassay (INNO-LIA™ HIV I/II Score) provides information on the duration of infection, which is unaffected
by clinical, immunological and viral variables. In this report we have set out to determine the diagnostic
performance of Inno-Lia algorithms for identifying incident infections in patients with known duration of infection
and evaluated the algorithms in annual cohorts of HIV notifications.
Methods: Diagnostic sensitivity was determined in 527 treatment-naive patients infected for up to 12 months.
Specificity was determined in 740 patients infected for longer than 12 months. Plasma was tested by Inno-Lia and
classified as either incident (< = 12 m) or older infection by 26 different algorithms. Incident infection rates (IIR)
were calculated based on diagnostic sensitivity and specificity of each algorithm and the rule that the total of
incident results is the sum of true-incident and false-incident results, which can be calculated by means of the pre-
determined sensitivity and specificity.
Results: The 10 best algorithms had a mean raw sensitivity of 59.4% and a mean specificity of 95.1%. Adjustment
for overrepresentation of patients in the first quarter year of infection further reduced the sensitivity. In the
preferred model, the mean adjusted sensitivity was 37.4%. Application of the 10 best algorithms to four annual
cohorts of HIV-1 notifications totalling 2’595 patients yielded a mean IIR of 0.35 in 2005/6 (baseline) and of 0.45,
0.42 and 0.35 in 2008, 2009 and 2010, respectively. The increase between baseline and 2008 and the ensuing
decreases were highly significant. Other adjustment models yielded different absolute IIR, although the relative
changes between the cohorts were identical for all models.
Conclusions: The method can be used for comparing IIR in annual cohorts of HIV notifications. The use of several
different algorithms in combination, each with its own sensitivity and specificity to detect incident infection, is
advisable as this reduces the impact of individual imperfections stemming primarily from relatively low sensitivities
and sampling bias.
Background
Information on the incidence of HIV infection is crucial
for monitoring the dynamics of the HIV epidemic in
affected countries. Consequently, serologic testing algo-
rithms for recent HIV seroconversion (STARHS) have
been developed [1-4]. These tests make use of the fact
that the HIV antibody response evolves during the first
few months of infection with respect to concentration
[5-7], proportion of the amount of total IgG [8], isotype
[9], and avidity [10]. The time during which these prop-
erties remain below a predetermined cutoff may greatly
differ individually, and its mean duration or ‘window-
period’ has to be established by testing specimens from
individuals with known date of HIV seroconversion [11].
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Estimation of the incidence in a population is based on
the relationship ‘Prevalence = Incidence × Duration’, as
described by others [4,12]. The performance of
STARHS, i.e. the sensitivity and specificity with which
they recognize or exclude an incident infection in an
individual patient is low and does not meet the stan-
dards required for tests used for diagnostic purposes.
Therefore, STARHS should not be used for individual
diagnosis. Recently, new procedures based on HIV
genetic diversity, as detected by single-genome analysis,
have been developed, which in the future may lead to
more reliable results also enabling diagnosis of incident
infection in individual patients [13-15].
STARHS require a special assay of reduced analytical
sensitivity; hence they are also called ‘detuned’ assays. The
reduced sensitivity renders these tests unsuitable for diag-
nosis of HIV infection and restricts their use to epidemio-
logical studies. However, for systematic epidemiologic
monitoring it would be convenient if information on inci-
dent infections could be gained prospectively and systema-
tically from the same tests used anyway to diagnose HIV.
We have previously shown that a patient’s antibody
reaction in a widely used commercial line immunoassay,
the Inno-Lia™ HIV I/II Score (Inno-Lia), provides infor-
mation on the duration of infection similar to that of a
commercial enzyme immunoassay (EIA), the so-called
BED Incidence EIA [8,16]. The Inno-Lia is a type of sec-
ond-generation Western blot (WB) that measures antibo-
dies to different HIV antigens in a semi-quantitative way
and is used for confirming HIV infection and to differenti-
ate between HIV-1 and HIV-2 [17,18]. Timely diagnosis of
HIV-2 is important, because this virus requires different
tests for viral load quantification than the widely used and
FDA-approved tests from Roche, Abbott, BioMérieux, or
Bayer. Furthermore, HIV-2 treatment requires different
antiretroviral drug regimens, as the virus is naturally resis-
tant to some frequently used drugs including the whole
class of non-nucleoside reverse transcriptase inhibitors
(NNRTI) [19-22]. In some countries, the Inno-Lia is thus
used routinely at the time of diagnosis, and in Switzerland
the test has become a mandatory confirmatory test for
HIV in 2006 [23].
As the pattern and intensity of HIV-specific antibodies
both evolve during the first weeks to months after infec-
tion, it is possible to define algorithms which differentiate
between early and late antibody patterns. Each of these
algorithms has its own characteristic sensitivity and speci-
ficity for detecting incident infections. Of note, the utiliza-
tion of the Inno-Lia results for population-based studies of
HIV-1 incidence comes at no additional costs – no addi-
tional test is needed.
As for STARHS, it is possible to determine window
periods for the different Inno-Lia antibody patterns seen
in early infection and to estimate the incidence based on
these windows. Work in this direction is in progress.
Alternatively, if the diagnostic sensitivity and specificity
of an algorithm are known, which requires prior testing
of suitable reference groups of infections of either less or
more than 12 months duration, it is also possible to esti-
mate the incidence by means of the basic diagnostic rule
ntested incident = ntrue incident + nfalse incident, whereby true-
incident and false-incident are calculated based on the
pre-determined values for diagnostic sensitivity and spe-
cificity [16]. The advantage of this approach is that the
imperfections of most diagnostic tests – a sensitivity and
a specificity below 100% – are already accounted for. In
contrast, with other STARHS and particularly the widely
used BED Incidence EIA [8], the incidence estimates
based on the relationship ‘Prevalence = Incidence ×
Duration’ are frequently too high [24-29]. Correction fac-
tors for imperfect sensitivity and specificity in both early,
i.e. patients who remain in recent state well beyond the
window period, and late stage infection, i.e., patients in
very advanced disease who return to recent state, have
had to be implemented [30-35]. This has required deter-
mination of the locally measured false-negative and false-
positive ratios, i.e. investigations of the same type as
those that are the basis of our true-incident/false-incident
approach.
A unique advantage of the Inno-Lia method is the fact
that it tests the antibody response to various HIV antigens
at the same time in a semi-quantitative way and therefore
allows identification of various antibody patterns that are
characteristic of early infection. Antibodies to five different
HIV-1 antigens are assessed in the test, allowing many
combinations characteristic of early stage infection to be
defined. Thus, a number of different algorithms, each with
its own sensitivity and specificity and yielding its own set
of samples ruled recent can be applied to a test popula-
tion, consequently reducing the sampling error associated
with a single test. As the Inno-Lia is a confirmatory HIV
test, it permits prospective testing of all newly diagnosed
patients and notification of the results to the respective
health authority, which may then periodically calculate the
proportion of recent infections among the notified new
cases or determine the incidence if the total number of
HIV tests performed is also known.
Precise information on the diagnostic sensitivity and
specificity of each algorithm is crucial for the method. If
these parameters are not correct, estimates of incident
infections will not be accurate. Originally, we estimated
these parameters in a study of newly diagnosed patients
with HIV-1 infection of either less or more than 12
months duration, as judged by the treating physicians of
these patients. As the study was prospective and no fol-
low-up data was available, it was uncertain whether these
judgments were correct. In this regard, the diagnostic
performance figures thus generated were of a preliminary
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nature, and the true diagnostic sensitivity and specificity
of the algorithms remain to be established. Furthermore,
as the specificity of STARHS might be impaired when
testing patients infected with non-B subtypes of HIV-1
[3] or in advanced disease, it was deemed necessary to
investigate whether or not these and other variables affect
the outcome of the algorithms.
We have conducted two studies aimed towards estab-
lishing this goal. One study, published elsewhere [36],
investigated the specificity of Inno-Lia algorithms in 714
patients of the Swiss HIV Cohort Study (SHCS) infected
for at least 12 months and representing all clinical stages
and major clades of HIV-1. That study showed that none
of these parameters affected the algorithms. Although a
viral RNA load below 50 copies/mL significantly reduced
the specificity among patients receiving ART, age was the
sole factor which could weakly impair the test specificity
in untreated patients.
The second study, presented here, now addresses the
diagnostic sensitivity of the Inno-Lia algorithms in a new
cohort of patients infected for less than one year. It also
investigates the overall diagnostic performance of the algo-
rithms, i.e., their ability to distinguish between incident
and older infection, and thus provides a basis for selecting
the best algorithms for assessing annual cohorts of HIV
notifications.
Methods
Ethics statement
The present study investigated patients of the Zurich Pri-
mary HIV Infection (ZPHI) study [37,38], the Swiss HIV
Cohort Study (SHCS)[39] and data from anonymized HIV
notifications to the Swiss Federal Office of Public Health
(SFOPH. The two studies were approved by the respective
ethical committees involved – the ZPHI by the ethical
committee of the Zurich University Hospital and the
SHCS by the ethical committees of all participating insti-
tutions (see http://www.shcs.ch). All participating patients
gave their written informed consent to the respective
study goals, which also include the present nested study.
No informed consent was required for the anonymized
notifications.
Patients with incident infection
Patients with HIV-1 infection of ≤ 12.0 months duration
(= recent or incident infection) were used for determina-
tion of the diagnostic sensitivity of the Inno-Lia algo-
rithms. These patients originated from either the ZPHI
study or the anonymized HIV notifications to the SFOPH
from April 2007 to December 2010.
The ZPHI study is an observational, open label, non-
randomized, single-center study (ClinicalTrials.gov iden-
tification no. NCT00537966) [40]. Patients with acute or
recent HIV-1 infection were included. Acute HIV-1
infection was defined as 1) presentation of the acute ret-
roviral syndrome (ARS) and a negative or indeterminate
WB or Inno-Lia results in the presence of a positive p24
antigen test and/or a detectable viral load; or 2) a docu-
mented seroconversion with or without symptoms no
more than 90 days ago. Recent infection was defined as
3) a possible ARS, a positive WB or Inno-Lia result,
detectable viral load, and a positive HIV gp120 avidity
respectively detuned assay result [41]; or 4) a documen-
ted acute HIV-1 infection with referral to our center
within 90 days after estimated date of infection (EDI).
For each patient, EDI was determined by taking into
account the pattern of different assay results (first posi-
tive and last negative HIV-test; negative, indeterminate
and positive WB; positive p24 Ag; antibody avidity assay),
patient’s reports of unambiguous risk contacts, and tim-
ing of onset of ARS symptoms. With respect to WB
results, the following rules were applied to determine the
EDI: (i) Negative WB (Fiebig stages I-III) [42]: If a single
risk contact was reported within the last three weeks
before the date of WB, this date was taken as EDI. In
contrast, if no history of risk contacts was reported, infec-
tion was assumed to have occurred 14 days before the
WB date. (ii) Indeterminate WB (Fiebig stage IV): If a
single risk contact was reported between 2 and 6 weeks
before the date of WB, this date was taken as EDI. In
case of several risk contacts, a higher and lower range
was estimated and the mean of this range was taken as
EDI. (iii) Positive WB (Fiebig stages V-VI): If a single risk
contact occurred 6 weeks or earlier before the date of the
WB, this date was taken as EDI if seroconversion was
documented. If a seroconversion within 6 months was
clearly documented without history of risk contact, the
mean date between the two tests (last negative and first
positive HIV-test) was taken as EDI. If a patient had a
history of an ARS, a fully converted WB, but no docu-
mented seroconversion and a negative detuned or avidity
assay, the EDI was defined as the date 20 days before the
onset of the ARS. These EDI definitions have been suc-
cessfully used and validated in previous publications
[14,38,40,43].
Incident infection among the HIV notifications was
identified as a case that met one of the following defini-
tions. (1) Laboratory evidence of seroconversion at the
time of diagnosis, i.e., a reactive 4th-generation HIV-1/2/
O antibody/p24 antigen combination screening test and a
positive virus component test (HIV-1 RNA or DNA or
p24 antigen) in combination with a negative 3rd-genera-
tion HIV-1/2/O antibody-only enzyme immunoassay
and/or a negative or indeterminate Inno-Lia result
according to the manufacturer’s instructions for result
interpretation. (2) A self-reported or documented nega-
tive HIV screening result no more than 12 months before
diagnosis. (3) Documented signs of ARS no more than
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90 days before diagnosis [44]. EDI among the notifica-
tions was defined as 14 days before the reported date of
onset of PHI symptoms or the mean date between the
last negative and first positive HIV-test.
Patients with older infection
Patients with HIV-1 infection of > 12.0 months duration
(= older infection) were needed for determination of the
diagnostic specificity of the algorithms. They were
selected from among either the SHCS or the HIV
notifications.
The SHCS patients, already investigated in a previous
study [36], had been infected with HIV-1 for at least 12
months, as shown by either a documented first positive
HIV test or registration into the SHCS at least 12 months
prior to sample date. The patients represented all major
clades of HIV-1 as well as the clinical stages and CD4+
strata. Virus concentrations were ≥50 HIV-1 RNA copies/
mL and thus sufficiently high not to lead to false-recent
antibody patterns [36]. Patients selected from the HIV
notifications met at least one of the following definitions:
(1) Presence of signs and symptoms of CDC stage B or C
or (2) progression to CDC stage C in the year of HIV diag-
nosis or the year thereafter.
Patients with unknown duration of infection
The majority of the SFOPH notifications consisted of
patients who did not meet the above-mentioned defini-
tions for incident or older infection. These cases of
unknown duration of HIV infection were utilized mainly
for the evaluation of the Inno-Lia algorithms in annual
notification cohorts. However, some of these notifications
also contained some kind of information on the duration
of infection, such as a negative HIV test earlier than 12
months before diagnosis or onset of presumed PHI at 4 to
12 months before diagnosis. EDI for these cases was deter-
mined in the same way as for the notifications classified as
incident infections.
Inno-Lia testing
ZPHI and SHCS samples were number-coded and tested
batch-wise by the Inno-Lia HIV I/II Score assay (Innoge-
netics, Ghent, Belgium). If there was more than one sam-
ple per patient, as was the case in the ZPHI study, the
latest available sample before onset of antiretroviral treat-
ment was selected. All retrospective Inno-Lia testing was
performed between October 2008 and January 2009. Noti-
fication samples were tested prospectively at the time of
diagnosis. All testing – prospective or retrospective – was
conducted in 11 HIV confirmatory labs commissioned by
the SFOPH or in the Swiss National Center for Retro-
viruses (SNCR), which serves as the national HIV refer-
ence laboratory and is also commissioned by the SFOPH.
All these laboratories are accredited according to the ISO/
IEC 17025 standard by the governmental Swiss Accredita-
tion Service SAS http://www.seco.admin.ch/sas/index.
html?lang=en. All labs had participated in previous colla-
borative studies of Inno-Lia based recent infection assess-
ment and were experienced with the test [16,36].
All Inno-Lia testing was performed according to the
manufacturer’s 16-h sample incubation protocol. The
Inno-Lia is a WB-like line immunoassay that measures
antibodies against recombinant proteins or synthetic pep-
tides of HIV-1 group M, HIV-1 group O, or HIV-2, which
are coated as 7 discrete lines on a nylon strip. As each test
strip also contains three quantitative internal standards, a
semi-quantitative ranking of the different antibody reac-
tions is possible [17,18]. Antibody reactions relevant for
assessment of recent infection status include those to
sgp120, gp41, p31, p24 and p17.
Collection of Inno-Lia results by means of HIV
notifications
Since September 2007, all newly diagnosed HIV patients
were notified to the SFOPH by means of a Microsoft
Excel® based electronic form. Anonymized personal iden-
tification and all available diagnostic data of each patient
including the detailed Inno-Lia results were entered into
this form by the 11 HIV notification labs or the SNCR and
forwarded by e-mail to the SFOPH. At the SFOPH, these
data were transferred into a database subsequently linked
with socio-epidemiological data from notifications
received from the treating physicians of the newly diag-
nosed patients and used for evaluation by the different
incident infection algorithms.
Incident infection algorithms
A total of 26 algorithms (Algs) for incident HIV-1 infec-
tion were employed. They had been developed by investi-
gating which Inno-Lia antibody patterns were found at
maximal frequency in patients with up to 12 months dura-
tion of infection and at minimal frequency in patients with
longer than 12 months of infection. Of the total, 24 algo-
rithms were as described [16,36], whereas Algs 11.2 and
15.1 were developed anew.
Calculation of the incident infection rate (IIR)
Calculation of the proportion of incident infections in
a population testing positive for HIV-1, the incident
infection rate (IIR), was based on the relationship
ntested incident = ntrue- incident + nfalse- incident, wherein
ntrue- incident = ntested × IIR × %Sensitivity/100 and
nfalse- incident = ntested × (1 - IIR) × (1 - %Specificity/
100). Therefore, equation #1 is: IIR = (ntested incident/
ntested + %Specificity/100 - 1)/(%Sensitivity/100 + %
Specificity/100 - 1) [16].
For calculating the IIR by means of the window-based
BED Incidence EIA, equation #2, as explained in detail
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elsewhere [1,45] was employed: IIR = ntested incident/
ntested × 365/window; using a window of 153 days, as
instructed by the test’s manufacturer, Calypte Biomedi-
cal Corporation, Lake Oswego, Oregon, USA.
Data evaluation and statistics
Inno-Lia results and clinical or socio-epidemiological data
were linked only after all testing was completed. Specifi-
city, sensitivity, total of correct results achieved with the
various incident infection algorithms and logistic likeli-
hood ratio (LLR) chi-square values were calculated by
means of contingency tables and logistic regression, as
contained in the StatView® 5.0 program for Macintosh
(SAS Institute Inc., Cary, North Carolina, U.S.A.). Stat-
View was also used to determine the result (incident or
older) of a sample by each of the 264 Inno-Lia algorithms.
Means were compared by paired or unpaired t-tests, as
specified under Results, and correlation was assessed by
Pearson’s test using Fisher’s r to z transformation.
Results
Plasma or serum samples from a total of 2’641 HIV-1
infected patients were tested by the Inno-Lia HIV I/II
Score assay, and the resulting antibody patterns were eval-
uated by 26 previously described recent infection algo-
rithms [36]. Out of the total, 527 patients (20.0%) met the
criteria for incident infection of up to 12 months duration
(see Methods), 740 (28.0%) those for older infection, and
the remaining 1’374 patients (52.0%) had an infection of
unknown duration. The main characteristics of the three
patient groups are summarized in Table 1.
Diagnostic sensitivity and specificity of the algorithms for
detecting incident infection
For determining the diagnostic sensitivity of the algo-
rithms, 527 samples obtained from treatment-naïve
patients with up to 12 months duration of HIV-1 infection
were available (Table 1, section A). These incident infec-
tion specimens included 144 from the ZPHI study and
383 from the HIV notifications (see Methods). The two
groups were similar with respect to the distributions of
sex, transmission risk, age, and concentration of HIV-1
RNA. Regarding duration of infection, the incident HIV
notification cases on average represented an earlier win-
dow of the infection than the ZPHI samples (p < 0.001;
unpaired t-test).
In order to determine the diagnostic specificity of the
algorithms, 740 samples from patients with infection
longer than 12 months were used (Table 1, section B).
Out of this total, 412 samples originated from the pre-
viously published SHCS study [36] and 328 samples origi-
nated from the HIV notifications (see Methods). The two
groups differed with respect to the distributions of sex,
transmission risk, age, and HIV-1 RNA load (unpaired
t-test; p < 0.01 for all). Furthermore, a majority of the
SHCS patients were receiving ART (which explains their
lower mean viral load), while all notification cases were
ART-naïve. All SHCS patients included in the analysis had
a viral load of 50 copies/mL or higher, because concentra-
tions below this limit were excluded due to their associa-
tion with false-recent results [36].
The diagnostic sensitivity of each of the 26 Inno-Lia
algorithms among the 527 incident infection samples is
depicted in Table 2. Also shown are the diagnostic specifi-
city among the 740 older infection samples, the percentage
of overall correct results, the logistic likelihood ratio (LLR)
chi-square value as a further measure of the diagnostic
performance, and the final rank of each algorithm. The
sensitivity of the algorithms extended from 20.3% for Alg3
to 63.95% for Alg4.1, while the specificity was between a
minimum of 90.80% for Alg6 and a maximum of 100% for
Algs 3 and 3.1. The newly developed Alg15.1 distinguished
best between incident and older infection. It exhibited a
sensitivity of 61.67%, a specificity of 95.14%, and it cor-
rectly classified 81.22% of the 1’267 samples (rank 1). The
respective LLR Chi-square value was 524.69 (rank 2), and
the sum of the two ranks was 3, thus placing Alg15.1 at
the top of all algorithms. A number of other algorithms
including Algs 15, 11.2, 13, 7, 9, 11.1, 12.1, 4.1, 12, 8.1 and
11 distinguished similarly well between incident and older
infection. As Algs 11 and 11.1 on the one hand and also
Algs 12 and 12.1 on the other hand were very similar to
each other, Algs 11 and 12 were further excluded, leaving
10 best Algs for use in further analyses. Depending on
whether the ranking was based on overall correct results
or LLR Chi-square, different though overlapping sets of
best algorithms would have been selected. It was thus jus-
tified to use both criteria in combination.
Adjustments for overrepresentation of very early incident
infections
The months of infection information in Table 1 indicates
that the incident infection samples were not distributed
evenly across the entire 12-months period of incident
infection, but concentrated within the first few months.
In order to assess the effect of the duration since EDI, we
separately analyzed the diagnostic sensitivity for each
quarter, using the selected 10 best algorithms on a total
of 621 patients for whom an EDI within the 12 months
preceding the diagnosis was known (Table 3). The analy-
sis included the 144 ZPHI patients and 477 notifications,
including 94 samples with a less precise EDI from section
C of Table 1. The number of cases in each quarter is
shown in the header of the table. The diagnostic sensitiv-
ity was relatively high in the first quarter, achieving a
mean of 71.3% (range 63.6 to 75.9%), but dropped to
means below 20% in the second, third and fourth quar-
ters. The true sensitivity in the third and fourth quarter
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Table 1 Overview of patient characteristics
A) Patients with incident infection (n = 527)
ZPHI patients HIV notifications
Number 144 383
Male (n, %) 129 (89.6) 332 (86.7)
Female (n, %) 15 (10.4) 51 (13.3)
Transmission risk (n, %)
MSM 102 (70.8) 242 (63.2)
HET 37 (25.7) 102 (26.6)
IVDU 4 (2.8) 17 (4.4)
OTH 1 (0.7) 0 (0)
Unknown 0 (0) 22 (5.7)
Age (median, IQR) 36 (30 - 42) 35 (28 - 43)
Months of infection (median, IQR) 1.59 (1.05 - 2.73) 1.04 (0.33 - 3.0)
HIV-1 RNA, (log [copies/mL]), IQR 5.1 (4.5 - 5.8) 5.2 (4.5 - 6.1)
CD4+ T cell count, cells/μL (median, IQR) 372 (270 - 552) n.a.
B) Patients with older infection (n = 740)
SHCS patients* HIV notifications
Number 412 328
Male (n, %) 205 (49.8) 231 (70.4)
Female (n, %) 207 (50.2) 97 (29.6)
Transmission risk (n, %)
MSM 54 (13.1) 90 (27.4)
HET 283 (68.7) 194 (59.1)
IVDU 48 (11.6) 16 (4.9)
OTH 24 (6.6) 6 (1.8)
Unknown 0 (0) 21 (6.4)
Age (median, IQR) 35 (30 - 41) 44 (34 - 53)
Days of infection (median, IQR) n.a. n.a. n.a. n.a.
HIV-1 RNA, (log [copies/mL]), IQR 3.9 (2.9 - 4.7) 5.16 (4.8 - 5.6)
CD4+ T cell count, cells/μL (median, IQR) 350 (208 - 544) n.a.
Treatment status
Prior to ART 190 (46.1) 328 (100)
Under ART 222 (53.9) 0 (0)
C) Notifications with unknown duration of infection (n = 1374)
Number 1374
Male (n, %) 924 (67.2)
Female (n, %) 423 (30.8)
Unknown 27 (2.0)
Transmission risk (n, %)
MSM 401 (29.2)
HET 472 (34.3)
IVDU 40 (2.9)
OTH 8 (0.6)
Unknown 453 (33.0)
Age (median, IQR) 36 (30 - 45)
HIV-1 RNA, (log [copies/mL]), IQR 4.8 (4.1 - 5.4)
n.a., not available; *same patients as investigated in [36]
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Table 2 Diagnostic performance of Inno-Lia algorithms for recent HIV-1 infection among the 1267 patients with
incident or older infection of Table 1
Alg
#
Definition Sensitivity
%
Specificity
%
Overall correct
%
(rank)
LLR Chi-
square
(rank)
Rank sum
(final
rank)
15.1 if (sgp120 ≤ 1 AND p31 ≤ 1 AND p17 ≤ p24)
OR (gp41 ≤ 2 AND p31 ≤ 1 AND p17 ≤ p24)
OR (p17 ≥ 2 AND p31 = 0 AND p17 ≤ p24)
OR (p31 = 0 AND p24 ≥ 2 AND p17 ≤ p24)
then RECENT
else older
61.67 95.14 81.22
(1)
524.69
(2)
3
(1)
15 if (sgp120 ≤ 1 AND p31 ≤ 1)
OR (gp41 ≤ 2 AND p31 ≤ 1)
OR (p17 ≥ 2 AND p31 = 0)
OR (p31 = 0 AND p24 ≥ 2)
then RECENT
else older
62.24 94.32 80.98
(2)
509.19
(4)
6
(2)
11.2 if (sgp120+gp41 ≤ 2.5)
OR ((sgp120+gp41+p31+p24+p17 ≤ 6.5) AND p31 ≤ 1 AND p17 ≤
p24)
OR (p31 = 0 AND p24 ≥ 2)
then RECENT
else older
61.48 94.05 80.51
(3)
490.62
(6)
9
(3.5)
13 if (sgp120+gp41 ≤ 4 AND p31 = 0)
OR (p31 = 0 AND p24 ≥ 2)
then RECENT
else older
59.77 95.00 80.35
(4)
493.18
(5)
9
(3.5)
7 if sgp120+gp41+p31 ≤ 4
then RECENT
else older
54.08 98.38 79.95
(10.5)
530.11
(1)
11.5
(5)
9 if sgp120+gp41 ≤ 4 AND p31 = 0
then RECENT
else older
52.75 98.38 79.40
(12)
511.40
(3)
15
(6)
11.1 if (sgp120+gp41 ≤ 2.5)
OR ((sgp120+gp41+p31+p24+p17 ≤ 6.5) AND p31 ≤ 1
OR (p31 = 0 AND p24 ≥ 2)
then RECENT
else older
61.48 93.51 80.19
(6.5)
475.99
(9)
15.5
(7)
12.1 if (p24 ≥ 2 AND p31 = 0)
OR (gp41 ≤ .5)
OR (sgp120+gp41+p31 ≤ 4)
OR (p31 ≤ 1 AND (sgp120+gp41+p31+p24+p17 ≤ 6.5))
then RECENT
else older
61.67 93.38 80.19
(6.5)
475.12
(10)
16.5
(8)
4.1 if p31 ≤ 0.5
then RECENT
else older
63.95 91.89 80.27
(5)
470.01
(14)
19
(9.5)
12 if (p24 ≥ 2 AND p31 = 0)
OR (gp41 ≤ .5)
OR (sgp120+gp41+p31 ≤ 4
OR sgp120+gp41+p31+p24+p17 ≤ 6.5)
then RECENT
else older
61.67 93.37 80.17
(8)
474.55
(11)
19
(9.5)
8.1 if gp41 ≤ 0.5
OR (sgp120+gp41+p31 ≤ 4)
OR ((sgp120+gp41+p31+p24+p17 ≤ 6.5) AND p31 ≤ 1)
then RECENT
else older
54.65 96.76 79.24
(13)
476.63
(7)
20
(11)
11 if (sgp120+gp41 ≤ 2.5)
OR (sgp120+gp41+p31+p24+p17 ≤ 6.5)
OR (p31 = 0 AND p24 ≥ 2)
then RECENT
else older
61.48 93.37 80.09
(9)
471.87
(12)
21
(12)
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was most likely even lower, as all of the 22 notification
samples ruled incident by at least one algorithm were
placed into these quarters because of a negative HIV test
12 to 24 months before diagnosis, thus yielding a mid-
point of 6 to 12 months before diagnosis. In contrast,
none of the better characterized 15 ZPHI patients placed
within these two quarters was ruled recently infected (2
× 2 table test; p < 0.05).
Although the diagnostic sensitivity in these later quar-
ters of the incident infection period can thus not be
established accurately, it is clear that the raw sensitivities
of Table 2 (shown again in column S0 of Table 3) do not
apply to them, and a bias would be introduced if the
effect of duration since EDI were not adjusted for. Thus,
we developed several models for adjusting the raw sensi-
tivities. In the first adjustment model, we obtained
Table 2 Diagnostic performance of Inno-Lia algorithms for recent HIV-1 infection among the 1267 patients with inci-
dent or older infection of Table 1 (Continued)
8 if gp41 ≤ 0.5
OR (sgp120+gp41+p31 ≤ 4)
OR (sgp120+gp41+p31+p24+p17 ≤ 6.5)
then RECENT
else older
54.65 96.75 79.23
(14)
476.13
(8)
22
(13)
13.1 if gp41 ≤ 2
OR (p31 = 0 AND p24 ≥ 2)
then recent
else older
60.34 93.92 79.95
(10.5)
470.77
(13)
23.5
(14)
3 if gp41 ≤ 0.5
then RECENT
else older
20.30 100.0 66.85
(25)
201.79
(23)
24.5
(22)
4 if p31 = 0
then RECENT
else older
60.15 92.70 79.16
(15)
436.83
(16)
31
(15)
17 if (sgp120 * gp41) ≤ 2
then RECENT
else older
50.09 98.24 78.22
(17)
469.33
(15)
32
(16)
2 if sgp120 ≤ 1
then RECENT
else older
54.46 95.41 78.37
(16)
431.97
(17)
33
(17)
16 if (sgp120 ≤ 1 AND (p31+p24+p17 ≤ 2.5))
OR (gp41 ≤ 1)
OR (p31 ≤ 0.5 AND (sgp120+gp41+p24+p17 ≥ 15))
OR (p24 = 0 AND gp41 ≤ 2)
OR (p24 ≥ 3 AND p31 = 0)
then RECENT
else older
50.47 96.62 77.43
(18)
416.47
(19)
37
(18.5)
18 if (sgp120 * gp41 ≤ 1)
OR (p24+p31 = 0)
then RECENT
else older
46.11 98.24 76.56
(19)
416.96
(18)
37
(18.5)
14 if (sgp120+gp41+p31+p24+p17 ≤ 6.5 AND p31 ≤ 1)
then RECENT
else older
45.92 97.84 76.24
(20)
399.26
(20)
40
(20)
3.2 if gp41 ≤ 2
then RECENT
else older
44.02 98.11 75.61
(21)
385.38
(21)
42
(21)
6 if p17 = 0
then RECENT
else older
40.80 90.80 69.98
(22)
178.75
(24)
46
(22.5)
3.1 if gp41 ≤ 1
then RECENT
else older
23.53 100.0 68.19
(24)
236.77
(22)
46
(22.5)
10 if p31 = 0 AND p24 ≥ 2
then RECENT
else older
30.93 95.27 68.51
(23)
164.49
(25)
48
(24.5)
5 if p24 ≤ 0
then RECENT
else older
26.00 95.54 66.61
(26)
125.29
(26)
52
(26)
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Table 3 Diagnostic sensitivity of the 10 best algorithms per quarter of incident infection
Alg
#
Non-adjusted sensitivity S0 Quarter
1
n = 406
Quarter
2
n = 112
Quarter
3
n = 58
Quarter
4
n = 45
Adjusted sensitivity S1 Adjusted sensitivity S2 Adjusted sensitivity S3
4.1 63.95 75.86 22.30 22.40 17.80 34.6 55.1 42.1
15 62.24 74.88 20.50 17.20 17.80 32.6 53.6 40.2
15.1 61.67 74.14 20.50 17.20 15.60 31.9 52.9 39.6
12.1 61.67 74.14 20.50 15.50 15.60 31.4 52.8 39.3
11.2 61.48 73.89 20.50 15.50 15.60 31.4 52.6 39.2
11.1 61.48 73.89 20.50 15.50 15.60 31.4 52.6 39.2
13 59.77 71.92 18.80 13.80 15.60 30.0 50.9 37.7
8.1 54.65 65.76 17.90 10.30 6.70 25.2 45.8 33.1
7 54.08 65.27 16.10 10.30 6.70 24.6 45.2 32.4
9 52.75 63.55 16.10 8.60 6.70 23.7 43.9 31.4
Mean 59.37 71.33 19.4 14.6 13.4 29.7 50.5 37.4
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adjusted sensitivities S1 simply by averaging the four
quarter sensitivities. This corresponds to a model that
assumes an even distribution of diagnosing incident
infections over all four quarters. The respective adjusted
sensitivities S1 extended from a maximum of 34.6% for
Alg4.1 to a minimum of 23.7% for Alg9. The mean S1,
29.7%, was roughly half the mean of S0. If the sensitivity
in quarters 3 and 4 was set to zero, as suggested by the
results of the 15 ZPHI patients, mean S1 was reduced to
22.7%.
Obviously, however, the samples used in the analysis are
not distributed evenly among all four quarters and thus do
not contribute equal amounts of information for estimat-
ing overall sensitivities, leading to a further potential bias.
We therefore made further adjustments by weighting the
contribution of each quarter to the overall sensitivity. The
analysis was restricted to the HIV notifications, as these
are representative with respect to the duration of the
newly diagnosed infections. Weighting was based on the
number of the notifications in each quarter. In our second
adjustment model, we considered all three definitions for
an incident infection (i.e., laboratory, clinical, and based
on a negative test). In the third model, we excluded all
cases judged incident because of reported signs or symp-
toms of ARS (incidence definition 3 for the HIV notifica-
tions in Methods) and considered only the notifications
with a previous negative HIV test. Model 3 thus did not
select for symptomatic acute infections.
With model 2, there were a total of 477 incident infec-
tions. Thirty-one of these were established based on lab
results, 225 were based on information regarding onset of
ARS, and 221 were based on a negative test within 24
months before diagnosis. Two-hundred ninety-five of the
477 cases (61.8%) were in the first quarter, 94 (19.7%) in
the second, 50 (10.5%) in the third, and 38 (8.0%) in the
fourth. The adjusted, weighted sensitivities S2 were calcu-
lated by multiplying the quarter sensitivities with these
percentages and then averaging the products. They
extended from a minimum of 43.9% to a maximum of
55.1%; the mean was 50.5%. If, again, the sensitivity in
quarters 3 and 4 was set to zero, the mean S2 was reduced
to 47.9%.
With model 3, there were a total of 315 samples. Of
these, 120 (38.1%) were placed in the first quarter,
91 (28.9%) in the second, 57 (18.1%) in the third, and
47 (14.9%) in the fourth. When weighting the quarter sen-
sitivities with the respective percentages, the sensitivities
S3 were obtained. They extended from a minimum of
31.4% to a maximum of 42.1%, with a mean of 37.4%. A
reduction to a mean of 32.8% was obtained when assum-
ing a zero sensitivity for quarters 3 and 4.
In the context of calculating annual incident infection
rates in a population of interest, each of these models has
its merits and justifications, and we therefore used all of
them in parallel.
Application of algs for estimating the annual incident
infection rates (IIR)
Using the adjusted sensitivities S1, S2 or S3 in combination
with the specificities of Table 2 and employing equation
#1 of Methods, we calculated the IIR for the 10 best-per-
forming algorithms in four annual cohorts of newly diag-
nosed HIV-1 infections notified to the SFOPH (Additional
file 1). Based on which sensitivity was used, the mean IIR
at baseline (cohort A) varied between 0.246 and 0.453. For
2008 (cohort B), with each model, all 10 algorithms indi-
cated an increase of IIR averaging 30.6%, which was highly
significant (P < 0.0001; two-sided paired t-test). It should
be considered, however, that some of the algorithms are
similar and thus do not yield truly independent measure-
ments. For 2009 (cohort C), and again independently of
the sensitivity employed, six algorithms indicated a relative
decrease, while three indicated a further, modest increase
and one no change. Overall, this resulted in a mean IIR
that amounted to 121.9% of the IIR in cohort A. Com-
pared to 2008, the difference was weakly significant (P =
0.039; two-sided paired t-test). In 2010 (cohort D), all 10
algorithms again indicated a distinct decline to a mean IIR
back at baseline (P < 0.0001; two-sided t-test). When sen-
sitivities calculated on the assumption of a zero detection
rate in quarters 3 and 4 were used, the average IIR of the
four cohorts increased to 0.63, 0.82, 0.77 and 0.64 when
using S1, to 0.26, 0.34, 0.32 and 0.26 when using S2 and to
0.40, 0.52, 0.49 and 0.41 when using S3. In all these
instances, the relative differences between the four cohorts
were identical as shown in Additional file 1. Thus, the
relative changes between different annual cohorts were
independent of the absolute value of the diagnostic
sensitivity.
Although the 10 algorithms performed similarly – all
exhibited an increase between the baseline cohort and
2008 and a decline between 2009 and 2010, they dif-
fered to some degree with respect to the IIRs of the
four cohorts and even more with regard to the resulting
differences between them. This is illustrated in Figure 1,
which is based on the sensitivities S3; for details refer to
section C of the Additional file 1. For instance, the high-
est relative increase in the IIR between baseline and
2008 was from 0.312 to 0.459 for Alg8.1 (+46.9%), while
the smallest, for Alg4.1, was from 0.356 to 0.402
(+12.9%). Similarly, the individual IIRs for the period of
declining average IIR varied considerably. With Alg7,
there was a steep decline between 2008 and 2009, but
with Algs 12.1, 4.1, 11.1 and 11.2 there was either no
change or even a further increase. These differences
illustrate that a combination of several different
Schüpbach et al. BMC Infectious Diseases 2012, 12:88
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algorithms rather than a single one should be used for
determining the IIR.
Discussion
The purpose of the present study was to further assess the
diagnostic performance of Inno-Lia based algorithms for
incident HIV-1 infection and to see whether previous esti-
mates for sensitivity and specificity would be confirmed in
a new, much larger dataset of newly diagnosed patients
with no overlap to our first study [16]. In a recent study of
patients known to have been infected for at least one year,
we have demonstrated a high diagnostic specificity of the
algorithms, which was not affected by the HIV-1 clade or
the disease stage [36]. The present work also confirms the
high specificity of the algorithms (Table 2). Although the
specificities presented here are on average slightly lower
than those found previously (mean 95.74 vs. 96.47; P <
0.0001; paired t-test), they are of a similar magnitude, and
there is an excellent correlation across algorithms between
the earlier reported and new values (R = 0.983; P <
0.0001). As there is no follow-up among the notification
cases, the lower specificity in the present investigation
may be due to patients with severe acute retroviral syn-
drome, who were erroneously classified as CDC stages B
or C [46-48]. The small reduction has little impact on the
performance of the algorithms.
Regarding the diagnostic sensitivity, the raw sensitivities
in Table 2 are clearly overestimates of the sensitivities that
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Figure 1 Incident infection rates (IIR) in four annual cohorts of newly diagnosed HIV-1 infections based on adjusted sensitivity S3.
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would apply to a population of patients distributed evenly
over their first year of infection. The overestimation is due
to an overrepresentation of patients in the first three
months of infection, as is indicated by the numbers of
available samples shown in the header of Table 3. The
most important reason for this is that patients with symp-
tomatic ARS are preferentially diagnosed because they will
seek medical attention. Similarly, in case of a known expo-
sure to HIV, patients will seek to clarify their HIV status
as rapidly as possible, usually within 3 months, thereby
again favoring detection of their infection in the first quar-
ter. The only way to obtain reliable sensitivity rates for the
later quarters of the incident infection period is by follow-
up of patients diagnosed early and by subsequent repeated
testing during the entire first year of infection. This was
sought with the study of the ZPHI patients, but because
most of these patients opted for early ART, the number of
suitable samples representing the later quarters was small
and could not provide reliable results. This forced us to
rely predominantly on notification cases. For these, the
reliability of information on the EDI decreases with time
since the last negative HIV test or onset of ARS. Thus, the
sensitivity in quarters 3 and 4, and thus the overall diag-
nostic sensitivity of the algorithms, can currently not be
determined exactly, and Tables 3 and Additional file 1
illustrate the breadth of uncertainty that persists at this
stage.
The present investigation shows that the algorithms pre-
ferentially detect incident infections in their first quarter.
Here, the sensitivity was good, while in the second, third,
and fourth quarters it was low, as explained above. If
patients diagnosed in their first year of HIV infection were
distributed evenly across all four quarters, an adjustment
with equal weight for all quarter sensitivities, as is repre-
sented by sensitivity S1, would be appropriate. However,
the clear overrepresentation of samples in the first quarter
suggests that diagnosis of incident HIV infection is biased
towards the first few months. It is therefore advisable to
weight the quarter sensitivities with the proportion of
patients diagnosed in the respective quarter. We believe
that adjustment model 3, which yields the sensitivities S3,
is most appropriate, as it is based on a definition of inci-
dent infection that is not affected by symptoms of HIV
disease. Therefore, the later quarters are better repre-
sented than with model 2, while with model 1 they would
probably be overrepresented.
Using S3, our estimate of the incident infection rate in
the baseline cohort A of HIV notifications to the SFOPH
was remarkably close to a previous estimate, although
that earlier estimate was based on a different adjustment
method, which involved different sensitivities for early,
intermediate and late stages of incident infection [16]. In
that earlier approach we used Algs 9 and 12 and esti-
mated the IIR in cohort A at 0.33 and, respectively, 0.35.
In the present study, the IIR for these two algorithms
were 0.34 and 0.36, respectively, while the mean IIR
based on the 10 best algorithms was also 0.35 (see Addi-
tional file 1). In view of the different approaches, i.e., one
with reactivity-based and the other with time-based cor-
rections, the agreement of the two IIR estimates is
remarkable.
Advantages of using a combination of algorithms
One might argue that the simplest way of estimating the
IIR would be by selecting the best algorithm and using
only that best algorithm for all IIR calculations. However,
a closer inspection of Table 2 shows that it is difficult to
select a single best algorithm among the group of top-per-
forming algorithms. One also has to consider that the
best-performing algorithm in one population need not
necessarily be the best in a different one: Apart from diag-
nostic sensitivity and specificity, the proportion of overall
correct results depends highly on the true proportion of
incident infections in a test population. If that proportion
is low, a test with maximal specificity will prevail over one
with maximal sensitivity. Conversely, at a high proportion,
a test with maximal sensitivity will outperform one opti-
mized for specificity. Thus, these algorithms will work
optimally when used in combination. Figure 1 perfectly
illustrates this point by clearly demonstrating that it would
be impossible to select a best curve among the 10 shown.
It should also be considered, however, that the algorithms
are not truly independent of each other, and this has to be
kept in mind when performing statistical evaluations.
Whether one uses a single algorithm or a combination of
different ones has no effect on costs, as these population-
based evaluations are done in an automated way, e.g. by
entering the Inno-Lia dataset into a simple pre-formed
Excel table.
Comparison with the BED incidence EIA
Notification cohort A had originally also been tested by
the BED-EIA, which had ruled 262 of the 748 samples as
incident [16]. When using the BED-EIA in the sense of
its developers, i.e., based on a window of 153 days and
using equation #2 shown under Methods, an IIR of 0.84
was obtained. This was unacceptably high given the fact
that symptoms of CDC stages B or C, i.e. distinct mani-
festations of older infection, had been reported in 21.5%
of these notifications and that a sizable fraction of the
392 patients with no symptoms (52.4% of the total) must
also have been in the stage of older infection [16]. A
recent study conducted in Switzerland showed that 31%
of newly HIV diagnosed individuals presented with less
than 200 CD4+ T cells and 10% even with less than 50
CD4+ T cells per microliter [49]. We thus have to con-
clude that the BED-EIA derived, window-based IIR of
0.84 is grossly overestimated. This is in accordance with
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the findings of others, who also observed IIRs twice or
three times too high [27].
Of note, when the BED-EIA results were evaluated in
the same way as the Inno-Lia algorithms, i.e. based on the
test’s empirically determined sensitivity and specificity and
employing equation #1, an IIR of 0.37 was calculated
[8,16]. This was in excellent agreement with both our pre-
viously published and new Inno-Lia based estimates. The
question thus arises whether it would not be simpler to
use the BED assay in connection with IIR equation #1
instead of employing #2 and then having to correct for the
imperfect sensitivity and specificity of the test in the inves-
tigated population [12,29-35,50].
Changes in IIR over time
All 10 Inno-Lia algorithms indicated a distinct increase in
IIR for the notifications of 2008 compared to 2005/2006
and a decrease back to baseline in 2010 (Figure 1). Addi-
tional file 1 demonstrates that while the absolute IIR differ
considerably depending on the adjustment model for the
sensitivity, the relative differences between the different
annual cohorts are identical for all three models, as well as
for their further modifications based on the assumption of
a zero detection rate in quarters 3 and 4. Thus, when only
interested in changes in IIR over time, an exact knowledge
of the diagnostic sensitivity is not required. Nevertheless,
in view of the excellent agreement of previous and actual
IIR estimates in notification cohort A and the further
good agreement with the BED-based IIR in this cohort
when using equation 1, we clearly favor the sensitivities S3.
When used in conjunction with the specificities of Table
2, they should permit a continuous assessment of IIR
changes of different transmission risk groups over time in
Switzerland. This should also permit a timely evaluation of
the effectiveness of HIV prevention campaigns targeted at
different risk groups.
As the assessment of relative changes is not dependent
on the true sensitivity and because the Inno-Lia algorithms
are unaffected by HIV-1 clade and other variables that
affect the specificity of other STARHS [36], the method
should also be usable in countries other than Switzerland.
Caution is required, however, when using the method for
determination of absolute incident infection rates, and
further studies should be done.
Conclusions and limitations
In conclusion, we have determined the diagnostic perfor-
mance of 26 Inno-Lia algorithms for recent infection in
patients with verified recent or older HIV-1 infection.
Although the diagnostic sensitivity of some algorithms
determined here may lack ultimate precision despite our
correction for overrepresentation of 1st quarter samples,
the use of the 10 best-performing algorithms in combina-
tion permits minimization of the impact of their individual
limitations and the effects of sample bias and to monitor
changes in IIR in a population over time. As precise
knowledge of the diagnostic sensitivity is not required for
the assessment of such relative changes, the specificity and
adjusted sensitivity figures established here should also be
usable for similar studies in other regions of the world.
Our method is particularly attractive for countries in
which the Inno-Lia is already used as a confirmatory assay
and for differentiation between HIV-1 and HIV-2.
As our method is based on a distribution of early and
late infections that is characteristic of newly diagnosed
HIV-1 infections in a population including all ages of
adulthood, our method is not applicable to selected age
groups, e.g., young adults newly exposed to HIV risk
encounters. As explained above, the method should not
be used for determining absolute incident infection
rates. Finally, as the diagnostic performance of the
method, particularly the sensitivity of the algorithms,
does not meet the standards for tests used for diagnostic
purposes, the method is unsuitable for diagnosing inci-
dent or older infection in individual persons. The
method should only be used in population-based
studies.
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